21st International AIDS Conference (AIDS 2016)


Once-Daily Raltegravir and Dolutegravir-Based Dual-Drug Regimen Show Promise

August 12, 2016

On behalf of IFARA, Fred Schaich spoke with Pedro Cahn, M.D., Ph.D., about two late-breaking studies presented at this year's International AIDS Conference and about global funding for HIV. The first presentation reported on a clinical trial among 800 patients, two-thirds of whom were randomized to a once-daily formulation of raltegravir (Isentress) and one-third to the currently prescribed twice-daily version of the drug. It showed the new formulation to be non-inferior to current dosing.

The second presentation concerned a proof of concept study among 20 people with viral loads of 5,000-100,000 copies/mL who took a dual-drug regimen of dolutegravir (Tivicay, DTG) and lamivudine (3TC, Epivir). Viral loads among all study participants fell to below 400 copies/mL by week three and to undetectable (less than 50 copies/mL) at week eight. A randomized trial of 600 volunteers will now compare dolutegravir and tenofovir/FTC (Truvada) with dolutegravir/lamivudine. If successful, "we could really have a paradigm change in terms of initial therapy," because dolutegravir-based treatment is cheaper, less toxic and does not require monitoring, Cahn said.

The cost of treatment is a major issue for low- and middle-income countries, especially in light of most major donor countries' reducing their contributions. Cahn deplored that funding shortfall and called on developed nations to provide more funding for the Global Fund to Fight AIDS, Tuberculosis and Malaria instead of spending the money on bailing out banks and buying arms.

Watch the video to learn more:

About the panelist:

  • Pedro Cahn, M.D., Ph.D., Fundación Huésped and Buenos Aires University Medical School, Argentina

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.

Copyright © 2016 Remedy Health Media, LLC. All rights reserved.

Related Stories

Dual Therapy With Dolutegravir + 3TC Keep Viral Load Undetectable: 48-Week Results From PADDLE Study
Dolutegravir Is Superior to Boosted Atazanavir in Women in the ARIA Study
Once-Daily Raltegravir at Last Available: Week 48 Results From ONCEMRK Study

This article was provided by TheBodyPRO. It is a part of the publication The 21st International AIDS Conference (AIDS 2016).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.